1 January 2021 in International Journal of Pharmaceutics
RDRikeshwer Prasad Dewangan
Rikeshwer Prasad Dewangan
+2
26 October 2020 in Current Pharmaceutical Design
Parkinson’s disease is one of the most severe progressive neurodegenerative disorders, having a mortifying effect on the health of millions of people around the globe. The neural cells producing dopamine in the substantia nigra of the brain die out. This leads to symptoms like hypokinesia, rigidity, bradykinesia, and rest tremor. Parkinsonism cannot be cured, but the symptoms can be reduced with the intervention of medicinal drugs, surgical treatments, and physical therapies. Delivering drugs to the brain for treating Parkinson’s disease is very challenging. The blood-brain barrier acts as a highly selective semi-permeable barrier, which refrains the drug from reaching the brain. Conventional drug delivery systems used for Parkinson’s disease do not readily cross the blood barrier and further lead to several side-effects. Recent advancements in drug delivery technologies have facilitated drug delivery to the brain without flooding the bloodstream and by directly targeting the neurons. In the era of Nanotherapeutics, liposomes are an efficient drug delivery option for brain targeting. Liposomes facilitate the passage of drugs across the blood-brain barrier, enhances the efficacy of the drugs, and minimize the side effects related to it. The review aims at providing a broad updated view of the liposomes, which can be used for targeting Parkinson’s disease.
14 July 2020 in Environmental Chemistry Letters
1 November 2022 in Current Drug Targets
Background: The pathogenesis of hepatic diseases involves several cells which makes the delivery of pharmaceutical agents complicated. Many severe liver diseases affecting the worldwide population cannot be effectively treated. Major hindrance or challenges faced are natural physiological barriers and non-specific targeting of drugs administered leading to inefficient treatment. Hence, there is an earnest need to look for novel therapeutic strategies which can overcome these hindrances. Kind of literature have reported when a drug is incorporated inside or attached, to a polymeric material of either hydrophilic or lipophilic nature, drug safety and efficacy are incredibly raised. This has given the driving force to the dynamic investigation for development of novel biodegradable materials, drug delivery carriers, target specific drug delivery systems and many other novels approach. Objective: Present review is devoted to summarizing receptor-based liver cell targeting by the use of different modified novel synthetic drug delivery carriers. It also highlights recent progress in drug targeting to diseased liver mediated by various types of receptors including asialoglycoprotein, mannose and, galactose receptor, Fc receptor, low-density lipoprotein, glycyrrhetinic, and bile acid receptor. The essential consideration is given to the treatment of liver cancer targeting by the use of nanoparticulate systems, proteins, viral, and non-viral vectors, homing peptides and gene delivery. Conclusion: Receptors based targeting approach is one such approach that was explored by researchers to develop novel formulations which can ensure site specific drug delivery. Several receptors are present on the surfaces of liver cells which are reported to be highly overexpressed in the various disease conditions. Its all are helpful for the treatment of the liver cancer.